Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI blood test could spot deadly clotting complication in sepsis patients

NCT ID NCT07630415

Diagnosis Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to validate a new blood test that uses artificial intelligence to detect disseminated intravascular coagulation (DIC) early in patients with septic shock. DIC is a severe clotting disorder that often leads to death, but current diagnostic methods are complex and rarely used. The test measures a specific blood cell signal and combines it with AI to provide a faster, more reliable diagnosis. Researchers will enroll 492 adults in intensive care to see if this approach works better than existing tools.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
neutrophil fluorescence test and AI model
What this could lead to
If successful, this could give doctors a simple, fast blood test to catch a deadly complication of sepsis early, potentially saving lives.
What could go wrong
This is an early validation study, not a treatment trial. The test may not prove accurate enough in real-world intensive care settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 492 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted to the intensive care unit (ICU) for septic shock, with or without sepsis-associated disseminated intravascular coagulation (DIC), at the time of ICU admission.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ≥ 18 years old * Patient admitted to intensive care for septic shock * Patient affiliated with a social security scheme or having rights * No objection from the patient or a relative in case the patient is not able to express consent, or inclusion under emergency procedure in case the patient is not able to express their opinion and no relative of the patient is reachable. Exclusion Criteria: * Moribund patient on the day of inclusion * Child-Pugh C cirrhosis * Neutropenia (\<500 mm3) * Patient under legal protection * Patient under guardianship or curatorship * Pregnancy/ Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Disseminated intravascular coagulation (DIC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disseminated intravascular coagulation toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Disseminated intravascular coagulation (DIC) Reanimation Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University Hospitals of Strasbourg, Intensive Care Medicine Department - New Civil Hospital

    Strasbourg, 67098, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.